Back to Search
Start Over
Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment
- Source :
- International journal of STDAIDS. 31(10)
- Publication Year :
- 2020
-
Abstract
- Darunavir (DRV) is approved for once-daily use in patients with no DRV resistance-associated mutations (RAMs) and twice-daily use in those with DRV RAMs. Several studies suggest that once-daily DRV retains efficacy in the setting of 1–2 DRV RAMs whereas three or more DRV RAMs are needed for DRV resistance. There are few data to support the long-term use of once-daily DRV in patients with DRV RAMs. This observational study evaluated 48-week clinical outcomes of 22 treatment-experienced patients with ≥1 DRV RAMs switched to once-daily DRV between 2014 and 2017. The primary endpoint was HIV-1 RNA
- Subjects :
- Adult
Male
medicine.medical_specialty
Anti-HIV Agents
HIV Infections
Dermatology
030312 virology
Treatment experienced
Drug Administration Schedule
03 medical and health sciences
Internal medicine
Drug Resistance, Viral
Medicine
Humans
Pharmacology (medical)
In patient
Darunavir
0303 health sciences
030306 microbiology
business.industry
Public Health, Environmental and Occupational Health
HIV Protease Inhibitors
Middle Aged
Viral Load
CD4 Lymphocyte Count
Infectious Diseases
Treatment Outcome
Mutation
HIV-1
RNA, Viral
Once daily
business
medicine.drug
Subjects
Details
- ISSN :
- 17581052
- Volume :
- 31
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- International journal of STDAIDS
- Accession number :
- edsair.doi.dedup.....69c2401198be3497ea8488e5f776a1d7